Peregrine Asset Advisers Inc. bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,430 shares of the exchange traded fund’s stock, valued at approximately $217,000. Several other institutional […]
FFT Wealth Management LLC reduced its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 3.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 23,075 shares of the exchange traded fund’s stock after selling 882 shares during the period. FFT Wealth Management LLC’s holdings in […]
Y.D. More Investments Ltd raised its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 5,500.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,600 shares of the exchange traded fund’s stock after purchasing an additional 5,500 shares during the period. Y.D. More […]
Adell Harriman & Carpenter Inc. trimmed its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 15.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,123 shares of the exchange traded fund’s stock after selling 584 shares during the quarter. […]
Adell Harriman & Carpenter Inc. cut its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 15.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,123 shares of the exchange traded fund’s stock after selling 584 shares during the quarter. […]